Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: A feasible method with promising efficacy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 1, 2013, Pages 1-6

  Riga, Maria G ^a   Chelis, Leonidas ^a   Kakolyris, Stylianos ^a   Papadopoulos, Stergios ^a   Stathakidou, Sofia ^a   Chamalidou, Eleni ^a   Xenidis, Nikolaos ^a   Amarantidis, Kyriakos ^a   Dimopoulos, Prokopios ^a   Danielides, Vasilios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

acetylcysteine; cisplatin; otoprotection; ototoxicity; sensorineural hearing loss

Indexed keywords

ACETYLCYSTEINE; CISPLATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUDITORY THRESHOLD; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEARING ACUITY; HUMAN; HYDRATION; MALE; OTITIS; OTOTOXICITY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PURE TONE AUDIOMETRY; QUALITY OF LIFE; SINGLE BLIND PROCEDURE;

ACETYLCYSTEINE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; EAR; FEASIBILITY STUDIES; FEMALE; FREE RADICAL SCAVENGERS; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; TYMPANIC MEMBRANE; YOUNG ADULT;

EID: 84872919014     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31822e006d     Document Type: Article

References (47)

1. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: Antioxidant system. Pharmacol Toxicol. 1995;76: 386-394
2. Lee JE, Nakagawa T, Kim TS, et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol. 2004;124:1131-1135 (Pubitemid 40051560)
3. Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin induced ototoxicity and prevention. Hear Res. 2007;226: 157-167 (Pubitemid 46428033)
4. Rybak L. Cis-platinum associated hearing loss. J Laryngol Otol. 1981;95:745-747 (Pubitemid 11058823)
5. Vermorken J. Ototoxicity of cisdiamminedichloroplatinum (II): Influence of dose schedule and mode of administration. Eur J Cancer Clin Oncol. 1983;19:52-58
6. Dodd S, Dean O, Copolov DL, et al. N-acetylcysteine for antioxidant therapy: Pharmacology and clinical utility. Expert Opin Biol Ther. 2008;8:1955-1962
7. van den Berg JH, Beijnen JH, Balm AJ, et al. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev. 2006;32:390-397
8. Thomas Dickey D, Muldoon LL, Kraemer DF, et al. Protection against cisplatin ototoxicity by N-acetylcysteine in a rat model. Hear Res. 2004;193:25-30 (Pubitemid 38813422)
9. Korver KD, Rybak LP, Whitworth C, et al. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg. 2002;126:683-689 (Pubitemid 41115249)
10. Ekborn A, Hansson J, Ehrsson H, et al. High dose cisplatin with amifostine: Ototoxicity and pharmacokinetics. Laryngoscope. 2004;114:1660-1667 (Pubitemid 39278890)
11. Campbell KC, Rybak LP, Meech RP, et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90-98 (Pubitemid 26388984)
12. Planting AS, Catimel G, de Mulder PH, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer: EORTC Head and Neck Cooperative Group. Ann Oncol. 1999;10:693-700 (Pubitemid 29342375)
13. Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008;26:3749-3755
14. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493-500 (Pubitemid 32707970)
15. Weijl NI, Elsendoorn TJ, Lentjes EG, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised, double-blind, placebo-controlled study. Eur J Cancer. 2004;40:1713-1723 (Pubitemid 38902907)
16. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: A Children's Oncology Group study. Cancer. 2005;104:841-847 (Pubitemid 41113686)
17. Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther. 2005;312:424-431 (Pubitemid 40189538)
18. Lamperti A, Conger AD, Jenkins O, et al. WR-2721 entry into the brain across a modified blood-brain barrier. Radiat Res. 1988;115: 303-313
19. Treskes M, Holwerda U, Klein I, et al. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol. 1991;42:2125-2130
20. American Speech-Language Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36:11-19
21. Katzenstein HM, Chang KW, Krailo M, et al. Children's Oncology Group. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer. 2009;115:5828-5835
22. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22:441-445 (Pubitemid 40993608)
23. Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004;43:780-784 (Pubitemid 39557716)
24. Li G, Frenz DA, Brahmblatt S, et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology. 2001;22:163-176 (Pubitemid 32499698)
25. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355-1362 (Pubitemid 28140629)
26. Kopelman J, Budnick AS, Sessions RB, et al. Ototoxicity of highdose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope. 1988;98(8 Pt 1):858-864
27. Riedemann L, Lanvers C, Deuster D, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 2008;8:23-28
28. Gratton MA. The interaction of cisplatin and noise on the peripheral auditory system. Hear Res. 1990;50:211-224
29. Van der Hulst RJAM, Dreschler WA, Urbanus NAM. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol. 1988;97:133-137
30. Blakley BW, Gupta AK, Myers SF, et al. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg. 1994;120:541-546 (Pubitemid 24142680)
31. Schaefer S, Post JD, Close LG, et al. Ototoxicity of low and moderate dose cis-platinum. Cancer. 1985;56:1934-1939 (Pubitemid 15240862)
32. Laurell G, Jungnelius U. High dose cisplatin treatment: Hearing loss and plasma concentrations. Laryngoscope. 1990;100: 724-734 (Pubitemid 20222873)
33. Oldenburg J, Fossa° SD, Ikdahl T. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics. 2008;9: 1521-1530
34. Feghali JG, Liu W, Van De Water TR. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope. 2001;111:1147-1155 (Pubitemid 32625400)
35. Atkuri KR, Mantovani JJ, Herzenberg LA. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7:355-359 (Pubitemid 47289259)
36. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kB, and glutathione S-transferase gene expression. J Biol Chem. 1996;271:13422-13429 (Pubitemid 26185383)
37. Eastwood H, Pinder D, James D, et al. Permanent and transient effects of locally delivered n-acetyl cysteine in a guinea pig model of cochlear implantation. Hear Res. 2010;259:24-30
38. Munguia R, Sahmkow SI, Funnell WR, et al. Transtympanic Ringer's lactate application in the prevention of cisplatinuminduced ototoxicity in a chinchilla animal model. Otolaryngol Head Neck Surg. 2010;143:134-140
39. Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol. 2004;25:910-915 (Pubitemid 39491671)
40. Abi-Hachem RN, Zine A, Van De Water TR. The injured cochlea as a target for inflammatory processes, initiation of cell death pathways and application of related otoprotectives strategies. Recent Pat CNS Drug Discov. 2010;5:147-163
41. Tanaka F, Whitworth CA, Rybak LP. Round window pH manipulation alters the ototoxicity of systemic cisplatin. Hear Res. 2004;187:44-50 (Pubitemid 38091561)
42. Rademaker-Lakhai JM, Rademaker-Lakhai JM, Crul M, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006;24:918-924 (Pubitemid 46638845)
43. Konrad-Martin D, Konrad-Martin D, James KE, et al. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. J Am Acad Audiol. 2010;21:301-314
44. Duan M, Qiu J, Laurell G, et al. Dose and time-dependent protection of the antioxidant N-L-acetylcysteine against impulse noise trauma. Hear Res. 2004;2:1-9 (Pubitemid 38639826)
45. Grinberg L, Fibach E, Amer J, et al. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radic Biol Med. 2005;38:136-145 (Pubitemid 39626919)
46. Shi R, Huang CC, Aronstam RS, et al. N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacol. 2009; 9:7
47. Borkholder DA. State-of-the-art mechanisms of intracochlear drug delivery. Curr Opin Otolaryngol Head Neck Surg. 2008;16: 472-477